Notifications
Clear all

AAS for fat burning


QueenofDamned
(@queenofdamned)
Estimable Member
Joined: 10 months ago
Posts: 175
Topic starter  

Oral anabolic steroid treatment, but not parenteral androgen treatment, decreases abdominal fat in obese, older men.

Lovejoy JC, Bray GA, Greeson CS, Klemperer M, Morris J, Partington C, Tulley R.

Pennington Biomedical Research Center, Baton Rouge, Louisiana 70808-4124, USA.

OBJECTIVE: To compare the effects of Testosterone Enanthate (TE), anabolic steroid (AS) or placebo (PL) on regional fat distribution and health risk factors in obese middle-aged men undergoing weight loss by dietary means.

DESIGN: Randomized, double-blind, placebo-controlled clinical trial, carried out for 9 months with primary assessments at 3 month intervals. Due to adverse blood lipid changes, the AS group was switched from oral oxandrolone (ASOX) to parenteral nandrolone decaoate (ASND) after the 3 month assessment point. SUBJECTS: Thirty healthy, obese men, aged 40-60 years, with serum testosterone (T) levels in the low-normal range (2-5 ng/mL).

MAIN OUTCOME MEASURES: Abdominal fat distribution and thigh muscle volume by CT scan, body composition by dual energy X-ray absorptiometry (DEXA), insulin sensitivity by the Minimal Model method, blood lipids, blood chemistry, blood pressure, thyroid hormones and urological parameters.

RESULTS: After 3 months, there was a significantly greater decrease in subcutaneous (SQ) abdominal fat in the ASOX group compared to the TE and PL groups although body weight changes did not differ by treatment group. There was also a tendency for the ASOX group to exhibit greater losses in visceral fat, and the absolute level of visceral fat in this group was signi, Klemperer M, Morris J, Partington C, Tulley R.

Pennington Biomedical Research Center, Baton Rouge, Louisiana 70808-4124, USA.

OBJECTIVE: To compare the effects of testosterone enanthate (TE), anabolic steroid (AS) or placebo (PL) on regional fat distribution and health risk factors in obese middle-aged men undergoing weight loss by dietary means.

DESIGN: Randomized, double-blind, placebo-controlled clinical trial, carried out for 9 months with primary assessments at 3 month intervals. Due to adverse blood lipid changes, the AS group was switched from oral oxandrolone (ASOX) to parenteral nandrolone decaoate (ASND) after the 3 month assessment point. SUBJECTS: Thirty healthy, obese men, aged 40-60 years, with serum testosterone (T) levels in the low-normal range (2-5 ng/mL).

MAIN OUTCOME MEASURES: Abdominal fat distribution and thigh muscle volume by CT scan, body composition by dual energy X-ray absorptiometry (DEXA), insulin sensitivity by the Minimal Model method, blood lipids, blood chemistry, blood pressure, thyroid hormones and urological parameters.

RESULTS: After 3 months, there was a significantly greater decrease in subcutaneous (SQ) abdominal fat in the ASOX group compared to the TE and PL groups although body weight changes did not differ by treatment group. There was also a tendency for the ASOX group to exhibit greater losses in visceral fat, and the absolute level of visceral fat in this group was significantly lower at 3 months than in the TE and PL groups. There were significant main effects of treatment at 3 months on serum T and free T (increased in the TE group and decreased in the ASOX group) and on thyroid hormone parameters (T4 and t3 resin uptake significantly decreased in the ASOX group compared with the other two groups). There was a significant decrease in HDL-C, and increase in LDL-C in the ASOX group, which led to their being switched to the parenteral nandrolone decanoate (ASND) after 3 months. ASND had opposite effects on visceral fat from ASOX, producing a significant increase from 3 to 9 months while continuing to decrease SQ abdominal fat. ASND treatment also decreased thigh muscle area, while ASOX treatment increased high muscle. ASND reversed the effects of ASOX on lipoproteins and thyroid hormones. The previously reported effect of T to decrease visceral fat was not observed, in fact, visceral fat in the TE group increased slightly from 3 to 9 months, although SQ fat continued to decrease. Neither TE nor AS treatment resulted in any change in urologic parameters.

CONCLUSIONS: Oral oxandrolone decreased SQ abdominal fat more than TE or weight loss alone and also tended to produce favorable changes in visceral fat. TE and ASND injections given every 2 weeks had similar effects to weight loss alone on regional body fat. Most of the beneficial effects observed on metabolic and cardiovascular risk factors were dueficantly lower at 3 months than in the TE and PL groups. There were significant main effects of treatment at 3 months on serum T and free T (increased in the TE group and decreased in the ASOX group) and on thyroid hormone parameters (T4 and T3 resin uptake significantly decreased in the ASOX group compared with the other two groups). There was a significant decrease in HDL-C, and increase in LDL-C in the ASOX group, which led to their being switched to the parenteral nandrolone decanoate (ASND) after 3 months. ASND had opposite effects on visceral fat from ASOX, producing a significant increase from 3 to 9 months while continuing to decrease SQ abdominal fat. ASND treatment also decreased thigh muscle area, while ASOX treatment increased high muscle. ASND reversed the effects of ASOX on lipoproteins and thyroid hormones. The previously reported effect of T to decrease visceral fat was not observed, in fact, visceral fat in the TE group increased slightly from 3 to 9 months, although SQ fat continued to decrease. Neither TE nor AS treatment resulted in any change in urologic parameters.

CONCLUSIONS: Oral oxandrolone decreased SQ abdominal fat more than TE or weight loss alone and also tended to produce favorable changes in visceral fat. TE and ASND injections given every 2 weeks had similar effects to weight loss alone on regional body fat. Most of the beneficial effects observed on metabolic and cardiovascular risk factors were due to weight loss per se. These results suggest that SQ and visceral abdominal fat can be independently modulated by androgens and that at least some anabolic steroids are capable of influencing abdominal fat


Quote
slammer
(@slammer)
Trusted Member
Joined: 6 months ago
Posts: 83
 

Great post.....thanks


ReplyQuote
p.s.
 p.s.
(@p-s)
Eminent Member
Joined: 5 months ago
Posts: 39
 

I also agree that that was a great post.


ReplyQuote
Shadowman
(@shadowman)
New Member
Joined: 3 months ago
Posts: 2
 

I had to spend far too much time deciphering the summary. I think it states -

Oral Oxandrolone (with dieting) produces greater abdominal and visceral fat loss than Test enth, Nandolone Decanoate, and just dieting. All produced about the same weight changes.

But, Oxandrolone has negative side effects as follows:
- increases bad cholestrol (LDL)
- decrease good cholestrol (HDL)
- Thyroid hormones levels are suppressed


ReplyQuote
slammer
(@slammer)
Trusted Member
Joined: 6 months ago
Posts: 83
 

I had to spend far too much time deciphering the summary. I think it states -

Oral Oxandrolone (with dieting) produces greater abdominal and visceral fat loss than Test Enth, Nandolone Decanoate, and just dieting. All produced about the same weight changes.

But, Oxandrolone has negative side effects as follows:
- increases bad cholestrol (LDL)
- decrease good cholestrol (HDL)
- Thyroid hormones levels are suppressed

show me an AAS product that does not have a trade off...... :nono


ReplyQuote
Shadowman
(@shadowman)
New Member
Joined: 3 months ago
Posts: 2
 

The study is very interesting to me. I would like to run a cutting cycle and really burn the visceral and abdominal fat. Unfortunately, the summary does not mention dosage level to get the significant results.

I looked up Oxandrolone/Anavar in Anabolics 2004. It is a mild Anabolic with low Androgenic activity. In small doses it does not suppress natural T production. Bodybuilders use the steriod during cutting cycles. Anavar can be combined with primobolan and/or winstrol as well as Trenbolone to dramatically enhance the show physique. But you can bet that such a stack will suppress natural T production.

There is a hint of the study dosage in the claim that T levels were suppressed (at least moderate doses).

If you want my two cents, a stack of Testosterone Cypionate 200mg/wk, Anavar 20mg/day, and Trenbolone Cyp 100mg/week ought to rip the fat off your body. [Clenbutrol 20-100mcg (4-6 weeks) could added for a little extra punch. Maniacs could consider Cytomel 25-100mcg/day as well.]


ReplyQuote
Share: